VAM
RDHL

Visium Asset Management’s Redhill Biopharma RDHL Stock Holding History

Visium Asset Management’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-500
Closed -$6.13M – 464
2016
Q1 		$6.13M Hold
500
– – 0.1% 229
2015
Q4 		$6.44M Hold
500
– – 0.1% 240
2015
Q3 		$6.46M Buy
+500
New +$7.4M 0.09% 235

Other funds holding RDHL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
BHB
Bank Hapoalim BM Tel Aviv, Israel $652M AUM 19.01% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
FM
Family Management New York $834M AUM 20.83% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Visium Asset Management's RDHL Position: Q2 2016 in Review

Visium Asset Management sold out of Redhill Biopharma (RDHL) in Q2 2016, closing a stake of 500 shares — an estimated $6.13M sold.

Visium Asset Management first reported a position in RDHL in Q3 2015 and held it in 3 quarters. The position peaked at $6.46M in Q3 2015. 22 funds tracked by Wall St. Rank hold RDHL as of Q2 2016.

  • Visium Asset Management reported no remaining Redhill Biopharma position as of Q2 2016 after selling out during the quarter.
  • Visium Asset Management sold 500 Redhill Biopharma shares in Q2 2016, an estimated $6.13M.
  • Visium Asset Management first reported a position in Redhill Biopharma in Q3 2015 and held it in 3 quarters.
  • Visium Asset Management's Redhill Biopharma position peaked at $6.46M in Q3 2015.
  • 22 funds tracked by Wall St. Rank held Redhill Biopharma as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.